WallStreetZenWallStreetZen

NASDAQ: SNPX
Synaptogenix Inc Stock

Overview
EarningsRevenueDividendOwnership
$2.27+0.17 (+8.1%)
Updated Apr 23, 2025
SNPX Price
$2.27
Fair Value Price
N/A
Market Cap
$3.15M
52 Week Low
$1.84
52 Week High
$5.38
P/E
-0.21x
P/B
0.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.77M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.87
Operating Cash Flow
-$5M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SNPX Overview

Synaptogenix Incorporated is a biopharmaceutical company developing a product platform for the treatment of Alzheimer's based upon a drug candidate called Bryostatin-1. It is also assessing therapeutic applications of Bryostatin-1 for other neurodegenerative and cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-Pick Type C disease. Synaptogenix was incorporated in 2012 and is headquartered in New York, NY.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SNPX's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SNPX
RankedUnranked of 461

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.96A
Aurinia Pharmaceuticals (AUPH)
$8.09A
Catalyst Pharmaceuticals (CPRX)
$23.12A
View Top Biotech Stocks

Be the first to know about important SNPX news, forecast changes, insider trades & much more!

SNPX News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SNPX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SNPX is good value based on its book value relative to its share price (0.54x), compared to the US Biotechnology industry average (4.25x)
P/B vs Industry Valuation
SNPX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SNPX due diligence checks available for Premium users.

Valuation

SNPX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.21x
Industry
-284.95x
Market
26.95x

SNPX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.54x
Industry
4.25x
SNPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SNPX's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.5M
Profit Margin
0%
SNPX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$17.7M
Liabilities
$11.0M
Debt to equity
1.87
SNPX's short-term assets ($17.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNPX's short-term assets ($17.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNPX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SNPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.2M
Investing
$0.0
Financing
-$801.7k
SNPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SNPX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SNPX–$3.15M+8.25%-0.21x0.54x
ENVBD$3.19M+4.88%-0.07x2.00x
HEPA–$3.12M+1.43%-0.00x-1.67x
PALI–$3.11M+2.76%-0.07x0.42x
EYEN–$3.09M0.00%-0.02x-0.24x
View Top Biotech Stocks

Synaptogenix Stock FAQ

What is Synaptogenix's quote symbol?

(NASDAQ: SNPX) Synaptogenix trades on the NASDAQ under the ticker symbol SNPX. Synaptogenix stock quotes can also be displayed as NASDAQ: SNPX.

If you're new to stock investing, here's how to buy Synaptogenix stock.

What is the 52 week high and low for Synaptogenix (NASDAQ: SNPX)?

(NASDAQ: SNPX) Synaptogenix's 52-week high was $5.38, and its 52-week low was $1.84. It is currently -57.83% from its 52-week high and 23.32% from its 52-week low.

How much is Synaptogenix stock worth today?

(NASDAQ: SNPX) Synaptogenix currently has 1,389,815 outstanding shares. With Synaptogenix stock trading at $2.27 per share, the total value of Synaptogenix stock (market capitalization) is $3.15M.

Synaptogenix stock was originally listed at a price of $105.00 in Dec 9, 2020. If you had invested in Synaptogenix stock at $105.00, your return over the last 4 years would have been -97.84%, for an annualized return of -61.66% (not including any dividends or dividend reinvestments).

How much is Synaptogenix's stock price per share?

(NASDAQ: SNPX) Synaptogenix stock price per share is $2.27 today (as of Apr 23, 2025).

What is Synaptogenix's Market Cap?

(NASDAQ: SNPX) Synaptogenix's market cap is $3.15M, as of Apr 24, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Synaptogenix's market cap is calculated by multiplying SNPX's current stock price of $2.27 by SNPX's total outstanding shares of 1,389,815.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.